Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Vaccines

• Publication date

  2010-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/erv.10.106PMID 20822348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization.

  2010cited by this paper
• Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

  2010cited by this paper
• Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies

  2010cited by this paper
• Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.

  2010cited by this paper
• Novel Recombinant Mycobacterium bovis BCG, Ovine Atadenovirus, and Modified Vaccinia Virus Ankara Vaccines Combine To Induce Robust Human Immunodeficiency Virus-Specific CD4 and CD8 T-Cell Responses in Rhesus Macaques

  2010cited by this paper
• Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

  2010cited by this paper
• Mosaic Vaccines Elicit CD8+ T lymphocyte Responses in Monkeys that Confer Enhanced Immune Coverage of Diverse HIV Strains

  2010cited by this paper
• Host determinants of HIV-1 control in African Americans.

  2010cited by this paper
• A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).

  2010cited by this paper
• Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

  2010cited by this paper
• Genetic heterologous prime–boost vaccination strategies for improved systemic and mucosal immunity

  2009cited by this paper
• Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).

  2009cited by this paper
• Attenuated poxvirus vectors MVA and NYVAC as promising vaccine cadidates against HIV/AIDS

  2009cited by this paper
• OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial

  2009cited by this paper
• Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens

  2009cited by this paper
• Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

  2009cited by this paper
• Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity1

  2009cited by this paper
• The immune response during acute HIV-1 infection: clues for vaccine development

  2009cited by this paper
• Preclinical and Clinical Development of a Multi-Envelope, DNA-Virus-Protein (D-V-P) HIV-1 Vaccine

  2009cited by this paper
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Improved Survival in Rhesus Macaques Immunized with Modified Vaccinia Virus Ankara Recombinants Expressing Simian Immunodeficiency Virus Envelope Correlates with Reduction in Memory CD4+ T-Cell Loss and Higher Titers of Neutralizing Antibody

  2009cited by this paper
• Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge

  2009cited by this paper
• Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge

  2009cited by this paper
• Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers

  2009cited by this paper
• Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

  2009cited by this paper
• OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector

  2009cited by this paper
• Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B gag Vaccines in Healthy Adults

  2009cited by this paper
• Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination

  2009cited by this paper
• Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

  2009cited by this paper
• Preclinical Evaluation of the Immunogenicity of C-Type HIV-1-Based DNA and NYVAC Vaccines in the Balb/C Mouse Model

  2009cited by this paper
• A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers

  2009cited by this paper
• Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

  2009cited by this paper
• Plasmid-Encoded Interleukin-15 Receptor α Enhances Specific Immune Responses Induced by a DNA Vaccine In Vivo

  2009cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys

  2008cited by this paper
• EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

  2008cited by this paper
• HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

  2008cited by this paper
• DNA gag/Adenovirus Type 5 (Ad5) gag and Ad5 gag/Ad5 gag Vaccines Induce Distinct T-Cell Response Profiles

  2008cited by this paper
• Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

  2008cited by this paper
• HIV Vaccine Research: The Way Forward

  2008cited by this paper
• Failure of the Merck HIV vaccine: an uncertain step forward.

  2008cited by this paper
• Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

  2008cited by this paper
• Vaccines: correlates of vaccine-induced immunity.

  2008cited by this paper
• Measuring HIV-1-specific T cell immunity: how valid are current assays?

  2008cited by this paper
• DNA vaccines: developing new strategies to enhance immune responses

  2008cited by this paper
• Macaques vaccinated with live-attenuated SIV control replication of heterologous virus

  2008cited by this paper
• Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.

  2008cited by this paper
• Challenges in the development of an HIV-1 vaccine

  2008cited by this paper
• Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

  2008cited by this paper
• Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

  2008cited by this paper
• Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

  2008cited by this paper
• The challenge of HIV-1 subtype diversity.

  2008cited by this paper
• Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope

  2008cited by this paper
• Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.

  2008cited by this paper
• An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

  2008cited by this paper
• Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

  2008cited by this paper
• Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity.

  2008cited by this paper
• Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development

  2008cited by this paper
• Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120

  2007cited by this paper
• Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.

  2007cited by this paper
• A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (vCP1521) Prime With Oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 (CM235/SF2) Boost

  2007cited by this paper
• Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover

  2007cited by this paper
• Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.

  2007cited by this paper
• Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.

  2007cited by this paper
• Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

  2007cited by this paper
• Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

  2007cited by this paper
• Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

  2007cited by this paper
• Acceptability of A-CASI by HIV-Positive IDUs in a Multisite, Randomized, Controlled Trial of Behavioral Intervention (INSPIRE)

  2007cited by this paper
• Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.

  2007cited by this paper
• Preserved Central Memory and Activated Effector Memory CD4+ T-Cell Subsets in Human Immunodeficiency Virus Controllers: an ANRS EP36 Study

  2007cited by this paper
• Recognition of Escape Variants in ELISPOT Does Not Always Predict CD8+ T-Cell Recognition of Simian Immunodeficiency Virus-Infected Cells Expressing the Same Variant Sequences

  2007cited by this paper
• The science of adjuvants

  2007cited by this paper
• Enhanced Rates and Magnitude of Immune Responses Detected against an HIV Vaccine: Effect of Using an Optimized Process for Isolating PBMC

  2007cited by this paper
• Human Immunodeficiency Virus Type 1 Controllers but Not Noncontrollers Maintain CD4 T Cells Coexpressing Three Cytokines

  2007cited by this paper
• Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations

  2007cited by this paper
• Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

  2007cited by this paper
• A Phase I/II trial to assess the Safety and Imminogenicity of a plasmid DNA-MVA prime boost HIV-I vaccine candidate among healthy adult volunteers in Dar es Salaam, Tanzania.

  2007cited by this paper
• A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1

  2007cited by this paper
• Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels

  2006cited by this paper
• Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations

  2006cited by this paper
• Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

  2006cited by this paper
• HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

  2006cited by this paper
• Mucosal vaccines: the promise and the challenge

  2006cited by this paper
• HIV vaccines.

  2006cited by this paper
• Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.

  2006cited by this paper
• GP120: target for neutralizing HIV-1 antibodies.

  2006cited by this paper
• Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes

  2006cited by this paper
• Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys

  2006cited by this paper
• Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

  2006cited by this paper
• Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239

  2006cited by this paper
• Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

  2006cited by this paper
• The rational design of an AIDS vaccine.

  2006cited by this paper
• Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.

  2005cited by this paper
• Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV

  2005cited by this paper
• Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines

  2005cited by this paper
• Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

  2005cited by this paper
• Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag

  2005cited by this paper
• [HIV vaccines].

  2005cited by this paper
• HIV and SIV CTL escape: implications for vaccine design

  2004cited by this paper
• HIV vaccine design and the neutralizing antibody problem

  2004cited by this paper

• Protection Against Rabies Induced by the Non-Replicative Viral Vectors MVA and Ad5 Expressing Rabies Glycoprotein

  2025cites this paper
• Immunogenicity of HIV-1 Env-Gag VLP mRNA and Adenovirus Vector Vaccines in Mice

  2025cites this paper
• Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021

  2024cites this paper
• Vaccination against the Epstein–Barr virus

  2020cites this paper
• Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India

  2019cites this paper
• Recent advances on HIV DNA vaccines development : Stepwise improvements to clinical trials.

  2019cites this paper
• Novel prime-boost vaccine strategies against HIV-1

  2019cites this paper
• Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

  2018cites this paper
• DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.

  2018cites this paper
• CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation

  2018cites this paper
• Induction of Antibodies to HIV-1 Envelope Using Simian Adenovirus Vaccines

  2018cites this paper
• HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells

  2017cites this paper
• Immune Responses Induced by Immunization with HIV-1 DNA followed by HIV-Modified Vaccinia Virus Ankara with or without Recombinant gp 140 in Healthy Tanzanian Individuals THESIS FOR DOCTORAL DEGREE ( Ph . D . )

  2017cites this paper
• Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

  2016cites this paper
• Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

  2016cites this paper
• Characterization of the Antigen-Specific CD4+ T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes

  2015cites this paper
• HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies

  2015cites this paper
• A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults

  2015cites this paper
• Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy

  2015cites this paper
• Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen

  2015cites this paper
• Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

  2015cites this paper
• Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles

  2015cites this paper
• True Grit: Programmed Necrosis in Antiviral Host Defense, Inflammation, and Immunogenicity

  2014cites this paper
• Adenovirus Type 4 and 7 Vaccination or Adenovirus Type 4 Respiratory Infection Elicits Minimal Cross-Reactive Antibody Responses to Nonhuman Adenovirus Vaccine Vectors

  2014cites this paper
• This information is current as Immunogenicity Host Defense , Inflammation , and True Grit : Programmed Necrosis in Antiviral

  2014cites this paper
• Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.

  2014cites this paper
• Is prime boost strategy a promising approach in HIV vaccine development

  2014cites this paper
• Novel Vaccine Regimen Elicits Strong Airway Immune Responses and Control of Respiratory Syncytial Virus in Nonhuman Primates

  2014cites this paper
• Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms

  2014cites this paper
• Alphavirus replicon-based strategies for vaccination

  2014cites this paper
• PrimatesSyncytial Virus in Nonhuman Airway Immune Responses and Control of Novel Vaccine Regimen Elicits Strong

  2014cites this paper
• Protection from Simian AIDS T Cells in + on Virus-Specific CD8 Antibodies to gp120 and PD-1 Expression

  2014cites this paper
• Immunology and virology of HIV-1 infection in Cameroon

  2014cites this paper
• Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

  2014cites this paper
• Boosting Functional Avidity of CD8+ T Cells by Vaccinia Virus Vaccination Depends on Intrinsic T-Cell MyD88 Expression but Not the Inflammatory Milieu

  2014cites this paper
• Speci fi city and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modi fi ed Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

  2014cites this paper
• Prime-Boost Strategies in Mucosal Immunization Affect Local IgA Production and the Type of Th Response

  2013cites this paper
• Translation of Biomedical Prevention Strategies for HIV: Prospects and Pitfalls

  2013cites this paper
• Antibodies to gp120 and PD-1 Expression on Virus-Specific CD8+ T Cells in Protection from Simian AIDS

  2013cites this paper
• Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets

  2013cites this paper
• Expression of Human Rotavirus Chimeric Fusion Proteins from Replicating but Non Disseminating Adenovectors and Elicitation of Rotavirus-Specific Immune Responses in Mice

  2013cites this paper
• Novel directions in HIV-1 vaccines revealed from clinical trials.

  2013cites this paper
• Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors

  2013cites this paper
• Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1

  2013cites this paper
• Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

  2012cites this paper
• Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity

  2012cites this paper
• Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine

  2012cites this paper
• Design of therapeutic vaccines: hepatitis B as an example

  2012cites this paper
• Recombinant Influenza Vaccines

  2012cites this paper
• Protection against SHIV-KB9 Infection by Combining rDNA and rFPV Vaccines Based on HIV Multiepitope and p24 Protein in Chinese Rhesus Macaques

  2012cites this paper
• Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.

  2012cites this paper
• HIV epidemic in Asia: optimizing and expanding vaccine development

  2012cites this paper
• Region of HIV-1 Envelope Preferentially Target Epitopes within the V2 Regimen Induces T Cell Responses That The Thai Phase III Trial (RV144) Vaccine

  2012cites this paper
• The design and evaluation of HIV-1 vaccines.

  2012cites this paper
• Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.

  2012cites this paper
• The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

  2012cites this paper
• Human immunodeficiency virus vaccine trials.

  2012cites this paper
• Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses.

  2012cites this paper
• Biological and Immunological Characterization of Plant-Produced HIV-1 Gag/dgp41 Virus-Like Particles

  2011cites this paper
• Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

  2011cites this paper
• Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates

  2011cites this paper
• Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes

  2011cites this paper
• Construction, stability and immunogenicity of recombinant BCG expressing HIV-1 subtype C gag under the control of MtrA promoter, with or without the leader sequences

  2011cites this paper
• Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2

  2011cites this paper
• Evaluation of HIV testing strategies and monitoring of immune responses in HIV-vaccinated individuals in Tanzania

  2011cites this paper
• A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)

  2011cites this paper
• Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand

  2011cites this paper
• Genetic Analysis of the Near Full-Length Genome of an HIV Type 1 A1/C Unique Recombinant Form from Northern South Africa

  2011cites this paper
• Optimizing HIV‐1‐specific CD8+ T‐cell induction by recombinant BCG in prime‐boost regimens with heterologous viral vectors

  2011cites this paper
• Protective effect against toxoplasmosis in mice induced by DNA immunization with gene encoding Toxoplasma gondii ROP18.

  2011cites this paper
• Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

  2011cites this paper
• Plasmid-Encoded Interleukin-15 Receptor α Enhances Specific Immune Responses Induced by a DNA Vaccine In Vivo

  2009cites this paper